Kazia Therapeutics Ltd (KZIA) stock
KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30
$4.92−0.45 (-8.38%)
Close on Nov 20, 2026Market cap $7.96MP/E –Yield –
Kazia Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was A$42.00K, down 98.2% from the year before. The highest annual figure on record is A$15.18M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | A$42.00K | -98.2% |
| FY2024 | Jun 30, 2024 | A$2.31M | – |
| FY2023 | Jun 30, 2023 | A$0 | – |
| FY2022 | Jun 30, 2022 | A$0 | -100.0% |
| FY2021 | Jun 30, 2021 | A$15.18M | +12658.8% |
| FY2018 | Jun 30, 2018 | A$119.00K | -52.2% |
| FY2017 | Jun 30, 2017 | A$249.00K | -38.7% |
| FY2016 | Jun 30, 2016 | A$406.00K | – |
See a number that looks wrong?